Yumiko Ide

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto et al. · The Lancet Diabetes & Endocrinology · 2020 · 204 citations · Full text

Pioneer 9, Diabetes Management, Diabetes +9

Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study

Hisashi Yamanaka, Shigenori Tamaki, Yumiko Ide et al. · Annals of the Rheumatic Diseases · 2017 · 118 citations · Full text

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

Kohei Kaku, Hiroshi Maegawa, Yukio Tanizawa et al. · Diabetes Therapy · 2014 · 60 citations · Full text

β-Lactolin Enhances Neural Activity, Indicated by Event-Related P300 Amplitude, in Healthy Adults: A Randomized Controlled Trial

Ayana Kanatome, Yasuhisa Ano, Kazushi Shinagawa et al. · Journal of Alzheimer s Disease · 2021 · 14 citations · Full text

The Effect of Continuous Intake of Lactobacillus gasseri OLL2716 on Mild to Moderate Delayed Gastric Emptying: A Randomized Controlled Study

T. Ohtsu, Ken Haruma, Yumiko Ide et al. · Nutrients · 2021 · 13 citations · Full text